Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Alper Sevinç,1 Metin Özkan,2 Ahmet Özet,3 Faysal Dane,4 Berna Öksüzoğlu,5 Abdurrahman Işıkdoğan,6 Feyyaz Özdemir,7 Doğan Uncu,8 Mahmut Gümüş,9 Türkkan Evrensel,10 Arzu Yaren,11 Oğuz Kara,12 Salim Başol Tekin13 1Depar...

Full description

Bibliographic Details
Main Authors:	Sevinç A, Özkan M, Özet A, Dane F, Öksüzoğlu B, Işıkdoğan A, Özdemir F, Uncu D, Gümüş M, Evrensel T, Yaren A, Kara O, Tekin SB
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-01-01
Series:	OncoTargets and Therapy
Subjects:	Filgrastim neutropenia biosimilar original efficacy
Online Access:	https://www.dovepress.com/biosimilar-filgrastim-vs-filgrastim-a-multicenter-nationwide-observati-peer-reviewed-article-OTT

Similar Items

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
by: Roberto Hegg, et al.

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
by: Henri Roché, et al.
Published: (2018-11-01)

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz
by: McBride, Ali, et al.
Published: (2017)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018-08-01)

Clozapine re-challenge under the cover of Filgrastim
by: R Gopalakrishnan, et al.
Published: (2013-01-01)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
by: Reta Anggraeni Widya, et al.
Published: (2021-01-01)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019-10-01)

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Hendrik Wessels, et al.
Published: (2019-10-01)

Filgrastim Induced Severe Leukocytosis in Sepsis-Associated Leukopenia: A Case Repor
by: Foroud Shahbazi, et al.
Published: (2019-07-01)

Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
by: Cornes, P., et al.
Published: (2022)

Effect of Filgrastim on adult male rats’ fertility and reproductive performance
by: Sara Mohamed Saber, et al.
Published: (2021-04-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01)

Pancytopenia following rituximab therapy in a patient with rheumatoid arthritis: Could filgrastim be a temporary solution?
by: Robin George Manappallil
Published: (2016-08-01)

Chemomobilization with cyclophosphamide and filgrastim in multiple myeloma patients following lenalidomide treatment
by: Gerfen, Ashlee
Published: (2012)

Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
by: A V Rudakova, et al.
Published: (2016-06-01)

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
by: Karina Mendoza-Macedo, et al.
Published: (2016-11-01)

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial
by: Safa Najafi, et al.
Published: (2021-04-01)

A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation
by: Qixiang Ye, et al.
Published: (2018-05-01)

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
by: Dwight D. Eplin, et al.
Published: (2019-10-01)

Filgrastim (G-CSF) loaded liposomes: mathematical modeling and optimization of encapsulation efficiency and particle size
by: Farhad Kiafar, et al.
Published: (2016-12-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

Development and certification of an industrial reference standard for determination of filgrastim activity
by: E. V. Motuzova, et al.
Published: (2018-02-01)

Neupogen (Filgrastim) Induced Acute Hematuria/Proteinuria with 3 Days of Use in a 7-Year-old Boy Diagnosed as Aplastic Anemia
by: Sohail Azam, et al.
Published: (2020-07-01)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
by: Ka‐Won Kang, et al.
Published: (2020-09-01)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
by: Rocío Parody, et al.
Published: (2020-05-01)

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
by: Restelli U, et al.
Published: (2020-04-01)

The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer
by: Mustafa Buyukavci, et al.
Published: (2019-06-01)

Avaliação técnico-regulatória dos requisitos de qualidade para registro de medicamentos biológicos e biossimilares humanos: perspectivas e desafios no Brasil
by: Müller, Gabriela Guimarães
Published: (2019)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
by: Kalpna Desai, et al.
Published: (2018-09-01)

Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy
by: L Yu Vladimirova, et al.
Published: (2016-09-01)

Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
by: P V Krivorotko, et al.
Published: (2015-06-01)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
by: Yoshimura H, et al.
Published: (2017-01-01)

Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018-08-01)